☆ACUTA CAPITAL PARTNERS, LLC
Quality Q
0.146
AUM ($M)
143
Positions
23
Turnover
0.32
Top-10 wt
74%
Herfindahl
0.088
History (qtrs)
6
Excess Return
not eligible
AI Eval Run AI Eval
Holdings · 31 positions · portfolio value $143M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆PRAX funds › | PRAXIS PRECISION MEDICINES I | TRIM | — | 19.3% | -0.1% | 27.7 | 82,796 | -2,105 | 5 | — |
| ☆WHWK funds › | WHITEHAWK THERAPEUTICS INC | ADD | Common Stock | 15.0% | +6.6% | 21.5 | 4,685,912 | +1,275,510 | 5 | — |
| ☆TNGX funds › | TANGO THERAPEUTICS INC | TRIM | — | 8.5% | +1.9% | 12.2 | 390,949 | -50,882 | 3 | — |
| ☆STRO funds › | SUTRO BIOPHARMA INC | ADD | — | 6.3% | +1.5% | 9.0 | 270,251 | +826 | 3 | — |
| ☆AVBP funds › | ARRIVENT BIOPHARMA INC | NEW | — | 5.3% | +5.3% | 7.6 | 218,694 | +218,694 | 1 | — |
| ☆FDMT funds › | 4D MOLECULAR THERAPEUTICS INC | NEW | — | 4.7% | +4.7% | 6.8 | 507,801 | +507,801 | 1 | — |
| ☆DRUG funds › | BRIGHT MINDS BIOSCIENCES INC | TRIM | — | 4.5% | -1.3% | 6.5 | 92,745 | -19,251 | 5 | — |
| ☆OCUL funds › | OCULAR THERAPEUTIX INC | TRIM | — | 3.6% | +0.1% | 5.2 | 532,481 | -59,627 | 5 | — |
| ☆ERAS funds › | ERASCA INC | TRIM | — | 3.4% | -0.7% | 4.9 | 265,199 | -89,376 | 2 | — |
| ☆SRZN funds › | SURROZEN INC | ADD | — | 3.1% | -0.4% | 4.5 | 173,395 | +548 | 5 | — |
| ☆ARGX funds › | ARGEN SE - ADR | ADD | — | 3.0% | +0.6% | 4.4 | 4,705 | +15 | 5 | — |
| ☆MLTX funds › | MOONLAKE IMMUNOTHERAPEUTICS | ADD | — | 2.9% | +0.4% | 4.2 | 215,652 | +23,892 | 3 | — |
| ☆DSGN funds › | DESIGN THERAPEUTICS INC | ADD | — | 2.8% | +1.7% | 4.1 | 282,564 | +136,664 | 3 | — |
| ☆NERV funds › | MINERVA NEUROSCIENCES | HOLD | — | 2.7% | -0.3% | 3.9 | 709,500 | +0 | 3 | — |
| ☆TSHA funds › | TAYSHA GENE THERAPIES INC | ADD | — | 2.7% | +1.3% | 3.8 | 561,808 | +122,344 | 5 | — |
| ☆AVLN funds › | AVALYN PHARMA INC | NEW | — | 2.6% | +2.6% | 3.8 | 115,000 | +115,000 | 1 | — |
| ☆AVTX funds › | AVALO THERAPEUTICS INC | ADD | — | 2.4% | +1.8% | 3.4 | 186,308 | +125,500 | 2 | — |
| ☆AMLX funds › | AMYLYX PHARMACEUTICALS INC | ADD | — | 2.1% | +0.6% | 3.0 | 168,115 | +17,048 | 4 | — |
| ☆ARTV funds › | ARTIVA BIOTHERAPEUTICS INC | NEW | — | 1.8% | +1.8% | 2.5 | 260,416 | +260,416 | 1 | — |
| ☆CMPX funds › | COMPASS THERAPEUTICS INC | TRIM | — | 0.9% | -2.3% | 1.3 | 595,213 | -253,863 | 4 | — |
| ☆UTHR funds › | UNITED THERAPEUTICS CORP | HOLD | — | 0.8% | -0.1% | 1.2 | 2,224 | +0 | 4 | — |
| ☆CTNM funds › | CONTINEUM THERAPEUTICS INC-A | NEW | — | 0.7% | +0.7% | 1.0 | 63,095 | +63,095 | 1 | — |
| ☆LBRX funds › | LB PHARMACEUTICALS INC | HOLD | — | 0.7% | +0.1% | 0.9 | 28,919 | +0 | 4 | — |
| ☆MAZE funds › | MAZE THERAPEUTICS INC | EXIT | — | 0.0% | -0.4% | 0.0 | 0 | -19,335 | 0 | — |
| ☆UNCY funds › | UNICYCIVE THERAPEUTICS INC | EXIT | — | 0.0% | -0.3% | 0.0 | 0 | -57,959 | 0 | — |
| ☆TRDA funds › | ENTRADA THERAPEUTICS INC | EXIT | — | 0.0% | -0.8% | 0.0 | 0 | -89,358 | 0 | — |
| ☆OCS funds › | OCULIS HOLDING AG | EXIT | — | 0.0% | -1.9% | 0.0 | 0 | -98,339 | 0 | — |
| ☆IDYA funds › | IDEAYA BIOSCIENCES INC | EXIT | — | 0.0% | -1.1% | 0.0 | 0 | -48,234 | 0 | — |
| ☆RVMD funds › | REVOLUTION MEDICINES INC | EXIT | — | 0.0% | -1.8% | 0.0 | 0 | -26,069 | 0 | — |
| ☆CUSIP:880881107 funds › | TERNS PHARMACEUTICALS INC | EXIT | — | 0.0% | -18.6% | 0.0 | 0 | -495,772 | 0 | — |
| ☆CUSIP:35104E104 funds › | 4D MOLECULAR THERAPEUTICS INC | EXIT | — | 0.0% | -1.6% | 0.0 | 0 | -242,255 | 0 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 143 | 23 | 0.32 | 74% | 0.088 | 0.148 | — | in |
| 2026Q1 | 141 | 26 | 0.32 | 78% | 0.099 | 0.184 | — | in |
| 2025Q4 | 147 | 30 | 0.36 | 79% | 0.096 | 0.118 | — | in |
| 2025Q3 | 97 | 28 | 0.30 | 76% | 0.079 | 0.129 | — | in |
| 2025Q2 | 72 | 28 | 0.27 | 72% | 0.068 | 0.137 | — | entered |
| 2025Q1 | 86 | 34 | 0.00 | 65% | 0.053 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status